Skip to main content
Erschienen in: Investigational New Drugs 3/2017

01.02.2017 | SHORT REPORT

Surveillance of protocol deviations in Japanese oncology registration trials: a single institute experience

verfasst von: Shinsuke Sasada, Nobuko Ushirozawa, Noriko Kobayashi, Yutaka Fujiwara, Kenji Tamura, Noboru Yamamoto

Erschienen in: Investigational New Drugs | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Summary

Background The contents and requirements of study protocols vary depending upon each clinical registration trial. This study aims to describe details of protocol deviations in Japanese oncology registration trials. Methods We reviewed deviation reports that were discussed by the Institutional Review Board between 2010 and 2015. Results A total of 499 clinical trials were performed, from which 967 deviations were reported. In the initial 3 years, 445 deviations occurred in 535 ongoing trials, while 522 deviations occurred in 876 trials in the subsequent 3 years. The frequency of deviations related to visit, examination, treatment, and others was 189 (19.5%), 446 (46.1%), 275 (28.4%), and 57 (5.9%), respectively. Serious deviations were common at the time of registration of trials and during treatment. The deviations were attributable to the institution (n = 520), subject (n = 93), sponsor (n = 28), schedule management (n = 162), disease condition (n = 95), and others (n = 69). Conclusion This study showed the number and detail responsible factors of protocol deviations. Our findings support to distinguish between the measures to reduce the serious deviations and to reduce the overall number of deviations.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat (ICH) ICoH (1996) ICH harmonised tripartite guideline. Guideline for good clinical practice E6(R1) (ICH) ICoH (1996) ICH harmonised tripartite guideline. Guideline for good clinical practice E6(R1)
2.
Zurück zum Zitat Welfare MoHa (1997) Ministerial Ordinance. No. 28 (in Japanese) Welfare MoHa (1997) Ministerial Ordinance. No. 28 (in Japanese)
4.
Zurück zum Zitat Yonemori K, Hirakawa A, Ando M, Hirata T, Shimizu C, Katsumata N, Tamura K, Fujiwara Y (2011) Compliance with good clinical practice in oncology registration trials in Japan. Ann Oncol 22(6):1451–1456. doi:10.1093/annonc/mdq594 CrossRefPubMed Yonemori K, Hirakawa A, Ando M, Hirata T, Shimizu C, Katsumata N, Tamura K, Fujiwara Y (2011) Compliance with good clinical practice in oncology registration trials in Japan. Ann Oncol 22(6):1451–1456. doi:10.​1093/​annonc/​mdq594 CrossRefPubMed
5.
Zurück zum Zitat Saito K, Kodama Y, Ono S, Maida C, Fujimura A, Miyamoto E (2008) Reliability of Japanese clinical trials estimated from GCP audit findings. Int J Clin Pharmacol Ther 46(8):415–420CrossRefPubMed Saito K, Kodama Y, Ono S, Maida C, Fujimura A, Miyamoto E (2008) Reliability of Japanese clinical trials estimated from GCP audit findings. Int J Clin Pharmacol Ther 46(8):415–420CrossRefPubMed
6.
Zurück zum Zitat Saito K, Kodama Y, Ono S, Mutoh M, Kawashima S, Fujimura A (2006) Quality of Japanese clinical trials estimated from good clinical practice audit findings. Am J Ther 13(2):127–133CrossRefPubMed Saito K, Kodama Y, Ono S, Mutoh M, Kawashima S, Fujimura A (2006) Quality of Japanese clinical trials estimated from good clinical practice audit findings. Am J Ther 13(2):127–133CrossRefPubMed
9.
Zurück zum Zitat Ono S, Kodama Y, Nagao T, Toyoshima S (2002) The quality of conduct in Japanese clinical trials: deficiencies found in GCP inspections. Control Clin Trials 23(1):29–41CrossRefPubMed Ono S, Kodama Y, Nagao T, Toyoshima S (2002) The quality of conduct in Japanese clinical trials: deficiencies found in GCP inspections. Control Clin Trials 23(1):29–41CrossRefPubMed
11.
Zurück zum Zitat Akiyama T, Furuta M, Yamada H (2006) In order to perform clinical trials efficiently in Japan. Ann Jpn Respir Soc 44(8):541–549 Akiyama T, Furuta M, Yamada H (2006) In order to perform clinical trials efficiently in Japan. Ann Jpn Respir Soc 44(8):541–549
12.
Zurück zum Zitat Kaichi S, Oda T, Goto K, Sato K (2007) In order to perform clinical trials efficiently in Japan: important issues regarding monitoring by sponsors. Ann Jpn Respir Soc 45(11):829–835 Kaichi S, Oda T, Goto K, Sato K (2007) In order to perform clinical trials efficiently in Japan: important issues regarding monitoring by sponsors. Ann Jpn Respir Soc 45(11):829–835
13.
Zurück zum Zitat Nakahama Y, Terakado H, Fujiwara Y (2012) New trend for global clinical development. J Clin Ther Med 28(3):205–209 Nakahama Y, Terakado H, Fujiwara Y (2012) New trend for global clinical development. J Clin Ther Med 28(3):205–209
14.
Zurück zum Zitat Fujiwara Y (2007) Infrastructure development and human resources training for clinical trials. The national cancer center hospital as an example. Pharm Regul Sci 38:646–650 Fujiwara Y (2007) Infrastructure development and human resources training for clinical trials. The national cancer center hospital as an example. Pharm Regul Sci 38:646–650
15.
Zurück zum Zitat America IoMUCoQoHCi (2000) To Err Is Human: Building a Safer Health System. The National Academies Press, Washington, DC. doi:10.17226/9728 America IoMUCoQoHCi (2000) To Err Is Human: Building a Safer Health System. The National Academies Press, Washington, DC. doi:10.​17226/​9728
Metadaten
Titel
Surveillance of protocol deviations in Japanese oncology registration trials: a single institute experience
verfasst von
Shinsuke Sasada
Nobuko Ushirozawa
Noriko Kobayashi
Yutaka Fujiwara
Kenji Tamura
Noboru Yamamoto
Publikationsdatum
01.02.2017
Verlag
Springer US
Erschienen in
Investigational New Drugs / Ausgabe 3/2017
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-017-0434-3

Weitere Artikel der Ausgabe 3/2017

Investigational New Drugs 3/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.